(UroToday.com) The 2025 ASTRO annual meeting featured a biomarker breakthroughs prostate cancer session and a discussant presentation by Dr. Alan Dal Pra. Dr. Dal Pra noted that amongst the six ...

In intermediate risk prostate cancer patients randomized to short-term ADT and either 70 Gy or 76 Gy, testosterone recovery ...

(UroToday.com) The 2025 ASTRO annual meeting featured a predictive markers in prostate cancer session and a presentation by Dr. Melvin L. K. Chua discussing validation of a prognostic multimodal ...

The presence of adverse molecular features most closely correlated with genomic classifier scores, even within low grade tumors. There was an observed nearly 20-fold increase in the presence of ...

Primary physician reporting grade 2+ toxicity per CTCAE version 5.0 was the primary endpoint. Follow-up was performed 30 days post-treatment and subsequently every 3 to 4 months for 2 years: ...

The investigators hypothesized that the use of proton therapy for extended lymph node irradiation of the pelvic and ...

Dr. Sutera opened his talk by outlining that he would divide his presentation into three parts: first, defining MMAI; second, discussing its application in oligometastatic prostate cancer; and third, ...

The U54 ROBIN consortium is a first-of-its-kind effort to study the biological effects of radiation before, during, and after treatment, using small study cohorts for detailed molecular ...

Next, Dr. Mouw addressed the secondary analysis of the RAVES trial, which compared adjuvant and early salvage radiotherapy in ...

The 2025 ASTRO annual meeting featured a metastatic prostate cancer session and a discussant presentation by Dr. Comron ...

Enrollment was between October 2019 and December 2023, during which time 41 patients were assessed for eligibility and 32 patients were enrolled. The median age was 74.0 years (range: 61.0-82.0), the ...

The 2025 ASTRO annual meeting featured a clinical trials session and a presentation by Dr. Amar Kishan discussing the primary ...